Drug Development Targeting the Glycogen Synthase Kinase-3β (GSK-3β)-Mediated Signal Transduction Pathway: Role of GSK-3β in Adult Brain

Abstract Glycogen synthase kinase-3β (GSK-3β) is a constitutively active kinase. Since its activation results in neurofibrillary tangle (NFT) deposits in aged and Alzheimer’s disease (AD) brains, GSK-3β may be inhibited under normal conditions but activated under pathological conditions. Given its link to NFT formation, we sought to determine whether GSK-3β exists in the brain as a “pathological time bomb” that promotes disease development. To address this hypothesis, we analyzed GSK-3β heterozygote (GSK+/−) mice, which express GSK-3β at 50% wild-type levels. When tested in the Morris water maze test, GSK+/− mice surprisingly exhibited retrograde amnesia. Further analysis indicated that GSK+/− mice had impaired memory reconsolidation but normal memory consolidation. Therefore, we concluded that GSK-3β activation is required for memory reconsolidation in the adult brain.

[1]  Adam M. Campbell,et al.  Competitive interactions between endogenous LTD and LTP in the hippocampus underlie the storage of emotional memories and stress‐induced amnesia , 2005, Hippocampus.

[2]  Akihiko Takashima,et al.  GSK-3 is essential in the pathogenesis of Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.

[3]  C. Jack,et al.  Longitudinal characterization of two siblings with frontotemporal dementia and parkinsonism linked to chromosome 17 associated with the S305N tau mutation. , 2005, Brain : a journal of neurology.

[4]  Y. Dudai,et al.  Rites of Passage of the Engram Reconsolidation and the Lingering Consolidation Hypothesis , 2004, Neuron.

[5]  R G M Morris,et al.  Elements of a neurobiological theory of the hippocampus: the role of activity-dependent synaptic plasticity in memory. , 2003, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[6]  B. Everitt,et al.  Reconsolidation and Extinction of Conditioned Fear: Inhibition and Potentiation , 2006, The Journal of Neuroscience.

[7]  U. Frey,et al.  Synaptic tagging: implications for late maintenance of hippocampal long-term potentiation , 1998, Trends in Neurosciences.

[8]  J. Woodgett,et al.  Molecular cloning and expression of glycogen synthase kinase‐3/factor A. , 1990, The EMBO journal.

[9]  R. Jope,et al.  The multifaceted roles of glycogen synthase kinase 3β in cellular signaling , 2001, Progress in Neurobiology.

[10]  T. Bliss,et al.  Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice , 1999, Nature Neuroscience.

[11]  K. Imahori,et al.  Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[12]  A. Takashima,et al.  Hyperphosphorylated tau in parahippocampal cortex impairs place learning in aged mice expressing wild‐type human tau , 2007, The EMBO journal.

[13]  I. Grundke‐Iqbal,et al.  Molecular Mechanism of Alzheimer's Neurofibrillary Degeneration and Therapeutic Intervention a , 1996, Annals of the New York Academy of Sciences.

[14]  R. Jope,et al.  The glamour and gloom of glycogen synthase kinase-3. , 2004, Trends in biochemical sciences.

[15]  Jesús Avila,et al.  Glycogen synthase kinase 3: a drug target for CNS therapies , 2004, Journal of neurochemistry.

[16]  J. Lucas,et al.  Spatial learning deficit in transgenic mice that conditionally over‐express GSK‐3β in the brain but do not form tau filaments , 2002, Journal of neurochemistry.

[17]  P. S. Klein,et al.  Regulation of Glycogen Synthase Kinase-3 in Patients with Affective Disorders , 2007, Biological Psychiatry.

[18]  J. Woodgett,et al.  Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: Generation of paired helical filament epitopes and neuronal localisation of the kinase , 1992, Neuroscience Letters.

[19]  M. D. Forti,et al.  Schizophrenia as a GSK-3 dysregulation disorder , 2007, Trends in Neurosciences.

[20]  J. W. Rudy,et al.  Context memories and reactivation: constraints on the reconsolidation hypothesis. , 2004, Behavioral neuroscience.

[21]  W. Noble,et al.  Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Morris,et al.  Memory Reconsolidation: Sensitivity of Spatial Memory to Inhibition of Protein Synthesis in Dorsal Hippocampus during Encoding and Retrieval , 2006, Neuron.

[23]  G. Collingridge,et al.  LTP Inhibits LTD in the Hippocampus via Regulation of GSK3β , 2007, Neuron.

[24]  M. Roh,et al.  Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. , 2006, Current drug targets.

[25]  Jesús Avila,et al.  Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. , 2003, Journal of Alzheimer's disease : JAD.

[26]  J. Lucas,et al.  Cooexpression of FTDP-17 tau and GSK-3β in transgenic mice induce tau polymerization and neurodegeneration , 2006, Neurobiology of Aging.

[27]  Y. Dudai,et al.  Stability of Retrieved Memory: Inverse Correlation with Trace Dominance , 2003, Science.

[28]  K. Imahori,et al.  Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. , 1997, Journal of biochemistry.

[29]  T. Bliss,et al.  Glycogen synthase kinase‐3 inhibition is integral to long‐term potentiation , 2007, The European journal of neuroscience.

[30]  R A Crowther,et al.  Tau Proteins and Neurofibrillary Degeneration , 1991, Brain pathology.

[31]  A. Takashima,et al.  Activation of tau protein kinase I/glycogen synthase kinase-3β by amyloid β peptide (25–35) enhances phosphorylation of tau in hippocampal neurons , 1998, Neuroscience Research.

[32]  K. Imahori,et al.  Exposure of rat hippocampal neurons to amyloid β peptide (25–35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3β , 1996, Neuroscience Letters.

[33]  J. Trojanowski,et al.  The disordered neuronal cytoskeleton in Alzheimer's disease , 1992, Current Opinion in Neurobiology.

[34]  J. Lucas,et al.  Chronic lithium administration to FTDP‐17 tau and GSK‐3β overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre‐formed neurofibrillary tangles do not revert , 2006, Journal of neurochemistry.

[35]  J. Woodgett,et al.  Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation , 2000, Nature.